The long-term objective of the Pharmacology Shared Resource is to provide critical pharmacologic support, services, and expertise for Cancer Center investigators engaged in the development and evaluation of anticancer agents.
The specific aims of the Shared Resource are to provide the necessary services and expertise for: 1) the conduct of clinical pharmacokinetic studies performed through the vigorous NCI-funded Phase I and Phase II clinical trials programs in the Cancer Center, 2) for the conduct of pharmacogenetic studies performed in conjunction with appropriate early clinical trials and 3) for the conduct of preclinical pharmacology studies in support of Cancer Center investigator research. To accomplish these aims, the Shared Resource has state of the art capabilities and expertise for the sensitive and specific analysis of drugs and their metabolites in biological specimens, for structure elucidation and pharmacologic characterization of drug metabolites, for the conduct of clinical and preclinical pharmacokinetic studies using those assay methodologies, for the detailed analysis of pharmacokinetic data and for the conduct of pharmacogenetic studies using validated assays for determination of allelic variants of genes related to drug response. In addition. Shared Resource key personnel consult with Cancer Center investigators in the design of studies and the analysis and interpretation of pharmacologic data obtained in those studies. The services and expertise of this Shared Resource are available only to Cancer Center members and are prioritized based on funding source, nature of the studies (clinical or preclinical investigations), scientific needs of the investigator and priorities within the Cancer Center. The Director is responsible for overall selection, prioritization and oversight of activity within the Shared Resource. Conduct of specific experiments is assigned to laboratory personnel based on the nature of the proposed laboratory studies. The Shared Resource provides the mechanism to conduct all pharmacologic studies in one integrated environment with substantial scientific and economic efficiencies. During the current funding period, the Shared Resource has contributed to over 45 clinical pharmacology protocol-based studies in conjunction with Phase I and Phase II clinical trials encompassing pharmacokinetic and pharmacogenetic elements. The Shared Resource also provided preclinical pharmacologic support for 14 Cancer Center investigator-initiated laboratory projects either for grant-funded studies or in preparation for grant submissions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682935
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$197,230
Indirect Cost
$73,293
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434

Showing the most recent 10 out of 1129 publications